Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
Stocks · News reference
TD Cowen Reiterates Buy on Eli Lilly, Maintains $1250 Price Target
TD Cowen analyst Steve Scala reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $1250 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.